Deutsche Bank Aktiengesellschaft Reaffirms Hold Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SN)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday, Digital Look reports. They currently have a GBX 1,250 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 19.22% from the company’s previous close.

A number of other analysts also recently issued reports on SN. JPMorgan Chase & Co. cut their price objective on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a report on Thursday, August 6th. Royal Bank Of Canada lowered their target price on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a report on Thursday, August 6th. Citigroup cut Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. Berenberg Bank reduced their price target on Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research report on Friday, August 14th. Finally, Shore Capital Group restated a “buy” rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Smith & Nephew currently has an average rating of “Hold” and an average target price of GBX 1,293.33.

Smith & Nephew Stock Up 4.0%

Shares of LON:SN opened at GBX 1,048.50 on Tuesday. The stock’s 50-day moving average price is GBX 1,106.12 and its 200 day moving average price is GBX 1,155.57. The company has a current ratio of 2.14, a quick ratio of 0.84 and a debt-to-equity ratio of 73.07. The company has a market capitalization of £11.49 billion, a PE ratio of 37.75, a PEG ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.